France-based Ipsen have entered an exclusive licensing agreement with US-based Lexicon Pharmaceuticals to market telotristat etiprate outside of North America and Japan.

Lexicon will hold the rights to market telotristat etiprate in the US, Canada and Japan, which is being developed for the treatment of carcinoid syndrome.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Telotristat etiprate is an oral, small molecule inhibitor of tryptophan hydroxylase (TPH), which reduces peripheral serotonin production without affecting serotonin levels in the brain.

Lexicon CEO Lonnel Coats said: "This collaboration with Ipsen provides the opportunity to create added value for Lexicon and more effectively commercialize telotristat etiprate in markets around the world.

"Lexicon will hold the rights to market telotristat etiprate in the US, Canada and Japan, which is being developed for the treatment of carcinoid syndrome."

"Ipsen is a leader in the treatment of carcinoid syndrome and neuroendocrine tumours with Somatuline (lanreotide). Lexicon will benefit commercially from Ipsen’s substantial market presence in Europe and other countries in the licensed territory, and will benefit globally from coordination with Ipsen on medical and scientific matters."

Lexicon is currently carrying out Phase III clinical trials of telotristat for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumours, which produce large amounts of serotonin.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The US Food and Drug Administration (FDA) granted fast track status and orphan drug designation for telotristat, while European Medicines Agency (EMA) awarded orphan drug designation.

Ipsen CEO Marc de Garidel said: "Ipsen is delighted to enter into a partnership with Lexicon in Europe and other countries."

Lexicon is eligible to receive more than $145m, including $23m upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones, as part of the financial terms of the agreement.

The firm is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact